Open AccessPatient-tailored Drug-eluting Stent Choice – A Solution for Patients with Diabetes
Author(s) -
Roxana Mehran,
Antonio Colombo,
Pieter R. Stella,
Rafael Romaguera,
Gennaro Sardella
Publication year - 2015
Publication title -
interventional cardiology reviews research resources
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.832
H-Index - 11
eISSN - 1756-1485
pISSN - 1756-1477
DOI - 10.15420/icr.2015.10.03.158
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , stent , diabetes mellitus , percutaneous , drug eluting stent , coronary artery disease , cardiology , surgery , psychological intervention , restenosis , myocardial infarction , endocrinology , psychiatry
Although second-generation drug-eluting stents (DES) have improved outcomes in percutaneous coronary interventions (PCIs), important unmet needs remain. Two symposia at EuroPCR 2015 focused on two challenging scenarios. First, patients with diabetes mellitus (DM) have generally inferior outcomes following PCI. The Cre8™ stent (manufactured by CID Spa, member of Alvimedica Group) has shown unique efficacy in subpopulations of patients with DM during clinical trials. A live case in a patient with diabetes illustrated the challenges of complex multivessel disease. Second, optimising stent selection towards devices that have demonstrated complete and early endothelialisation offers the potential to reduce the duration of dual antiplatelet therapy. The Cre8™ DES features a polymer-free platform and has been associated with low rates of in-stent thrombosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom